Status:
COMPLETED
Comparison of Tenofovir Vaginal Gel and Film Formulations
Lead Sponsor:
CONRAD
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Healthy
HIV
Eligibility:
FEMALE
18-45 years
Phase:
EARLY_PHASE1
Brief Summary
This is an open label comparative study of tenofovir gel and film in 10 healthy sexually active women without active female genital tract disorders. The women will receive a single dose of each formul...
Detailed Description
This is an open label comparative study of tenofovir gel and film in 10 healthy sexually active women without active female genital tract disorders. The women will receive a single dose of each formul...
Eligibility Criteria
Inclusion
- 18 to 45 years of age (inclusive) with a history of receptive vaginal intercourse.
- HIV negative within 28 days of enrollment
- Understand and agree to local STI reporting requirements.
- Able and willing to provide written informed consent to take part in the study.
- Able and willing to provide adequate information for locator purposes.
- Availability to return for all study visits, barring unforeseen circumstances.
- Availability to return for the second formulation dosing at the same time in the subject's menstrual cycle as when the first formulation was administered, at least 10 days before menses.
- Willing to abstain from vaginal intercourse and insertion of anything (e.g., drug, vaginal douche, personal lubricant or sex toy) in vagina for 72 hours before each study product exposure, and 10 days following study product dosing, comprising a total of 26 days of abstinence, no insertion of vaginal products/objects while participating in the study.
- Willingness to have partner(s) use condoms (must not contain Nonoxynol-9) for the duration of the study.
- Agree not to participate in other research studies involving drugs and/or medical devices.
- Negative qualitative urine pregnancy test.
- Using an effective method of contraception at enrollment.
- Willingness to remain in the research unit for up to 12 hours on each of two dosing days.
Exclusion
- Current sexual partner known by participant to be HIV seropositive.
- Individuals who, by history, engage in condom-less intercourse with HIV-infected partners, or partners that have unknown HIV serostatus, or women who exchange sex for money, shelter, or gifts.
- Active chlamydia, gonorrhea, syphilis, trichomonas, cervicitis or PID within 8 weeks prior to enrollment.
- Individuals with active hepatitis B infection.
- Known history of genital HSV (diagnosed by either clinical or laboratory test).
- Symptomatic vaginal candidiasis or bacterial vaginosis.
- Undiagnosed irregular uterine bleeding
- Pathology of the female genital tract,
- Individuals who are status post hysterectomy.
- History of any cervicovaginal procedure (i.e. colposcopy with cervical biopsy) within the past 2 months.
- History of cone biopsy or extensive loop electrosurgical excision procedure (LEEP), which in the judgment of the investigator may affect permeability assessment.
- Any known primary or secondary uro-genital malformations, which in the assessment of the investigator may interfere with the intended urine collection for PK studies.
- Use of vaginally administered medications within 4 week of enrollment
- Any active urinary tract infection
- By history, subjects with irregular menstrual cycles.
- At screening:
- ALT or AST greater than 1.5 X the site laboratory ULN
- Hemoglobin less than 10.0 g/dL
- Platelet count less than 100,000/mm3
- Other safety tests outside of the normal range
- Findings that are clinically significant in the opinion of the investigator
- Estimated creatinine clearance \< 60 ml/min based on established nomograms
- Recent history (past 6 months) of injection drug use or alcohol use that may interfere with the study.
- Unwillingness to refrain from aspirin and NSAIDs product use for one week prior to and one week post study procedures.
- Use of warfarin or heparin.
- Use of systemic immunomodulatory medications within 4 weeks of enrollment.
- Use of product containing nonoxynol-9 within 4 weeks of enrollment.
- Use of any investigational products within 4 weeks of enrollment.
- Any other medical conditions deemed not safe for participation by the investigator.
- Any individual that is pregnant or is actively breast feeding.
- Post-menopausal defined as 12 months of amenorrhea.
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02280109
Start Date
November 1 2014
Last Update
January 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University School of Medicine Division of Clinical Pharmacology
Baltimore, Maryland, United States, 21287-5554